Literature DB >> 12920560

Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.

Spencer J Collis1, Kevin Khater, Theodore L DeWeese.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12920560     DOI： 10.1007/s00345-003-0363-y

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   3.661


× No keyword cloud information.
  178 in total

1.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins.

Authors:  L Rao; M Debbas; P Sabbatini; D Hockenbery; S Korsmeyer; E White
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

Authors:  J A McCart; J M Ward; J Lee; Y Hu; H R Alexander; S K Libutti; B Moss; D L Bartlett
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  Trojan peptides: the penetratin system for intracellular delivery.

Authors:  D Derossi; G Chassaing; A Prochiantz
Journal:  Trends Cell Biol       Date:  1998-02       Impact factor: 20.808

4.  An uncertain role for p53 gene alterations in human prostate cancers.

Authors:  J D Brooks; G S Bova; C M Ewing; S Piantadosi; B S Carter; J C Robinson; J I Epstein; W B Isaacs
Journal:  Cancer Res       Date:  1996-08-15       Impact factor: 12.701

5.  Development of synthetic promoters for radiation-mediated gene therapy.

Authors:  B Marples; S D Scott; J H Hendry; M J Embleton; L S Lashford; G P Margison
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

6.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

Authors:  D C Yu; Y Chen; M Seng; J Dilley; D R Henderson
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

Authors:  F Wong-Staal; E M Poeschla; D J Looney
Journal:  Hum Gene Ther       Date:  1998-11-01       Impact factor: 5.695

Review 9.  Adenoviral vector-mediated gene transfer for human gene therapy.

Authors:  B Breyer; W Jiang; H Cheng; L Zhou; R Paul; T Feng; T C He
Journal:  Curr Gene Ther       Date:  2001-07       Impact factor: 4.391

10.  Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.

Authors:  B Sischy; R L Doggett; J M Krall; D G Taylor; W T Sause; J A Lipsett; H G Seydel
Journal:  J Natl Cancer Inst       Date:  1989-06-07       Impact factor: 13.506
View more
  1 in total

1.  U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.

Authors:  Ekwere T Ifon; Alan L Y Pang; Warren Johnson; Kathleen Cashman; Sharon Zimmerman; Sumitra Muralidhar; Wai-Yee Chan; John Casey; Leonard Jason Rosenthal
Journal:  Cancer Cell Int       Date:  2005-06-22       Impact factor: 5.722
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.